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ABSTRACT 
Background. Acute respiratory distress syndrome (ARDS) is a life-threatening condition 
characterised by pulmonary oedema, respiratory failure and severe inflammation. ARDS is 
further characterised by the recruitment of neutrophils into the lung interstitium and alveolar 
space.  
Objectives. The factors that regulate neutrophil infiltration into the inflamed lung and our 
understanding of the pathomechanisms in ARDS remain incomplete. This study aimed to 
determine the role of the chemokines CCL2 and CCL7 in ARDS.  
Methods. CCL2 and CCL7 protein levels were measured in BAL fluid obtained from LPS-
challenged human volunteers and two separate cohorts of ARDS patients. Neutrophil 
chemotaxis to ARDS BAL fluid was evaluated and the contribution of each assessed and 
compared to CXCL8. Chemokine receptor expression on neutrophils from blood or BAL 
fluid of ARDS patients was analysed by flow cytometry. 
Results. CCL2 and CCL7 were significantly elevated in BAL fluid recovered from LPS-
challenged volunteers and ARDS patients. BAL fluid from ARDS patients was highly 
chemotactic for human neutrophils, and neutralising either CCL2 or CCL7 attenuated the 
neutrophil chemotactic response. Moreover, CCL2 and CCL7 synergised with CXCL8 to 
promote neutrophil migration. Furthermore, neutrophils isolated from the blood or BAL fluid 
differentially regulated the cell surface expression of CXCR1 and CCR2 during ARDS.  
Conclusion. This study highlights important inflammatory chemokines involved in 
regulating neutrophil migration, which may have potential value as therapeutic targets for the 
treatment of ARDS. 
  
What is the key question? 
To what extent do the chemokines, CCL2 and CCL7, contribute to the migratory activity of 
neutrophils during ARDS? 
What is the bottom line? 
Both CCL2 and CCL7 contribute to neutrophil chemotaxis during ARDS by synergising with 
CXCL8. 
Why read on?  
Excessive neutrophil recruitment during ARDS is associated with disease severity and poor 
clinical outcome, so therefore a clearer understanding of these pathomechanisms is urgently 
needed. 
 
 
Twitter 
Chemokines synergise to promote neutrophil migration in ARDS. New therapeutic targets.   
INTRODUCTION 
Acute respiratory distress syndrome (ARDS) is a life-threatening condition that is still 
associated with a high rate of mortality despite recent improvements in mechanical 
ventilation strategies and supportive care. ARDS is characterised by lung oedema, presenting 
as diffuse bilateral lung opacities, and hypoxemia that does not arise from cardiac failure or 
fluid overload.[1] ARDS can be classified as mild, moderate or severe, depending on the 
partial pressure of arterial oxygen to fraction of inspired oxygen ratios (PaO2/FIO2). ARDS 
remains a syndrome resulting from varied aetiologies and is associated with multiple 
pathologies, of which diffuse alveolar damage remains the most common pathognomonic 
feature.[2] 
 
Disease onset is often rapid and progressive, and usually the result of either a direct insult to 
the lung, such as pneumonia, aspiration of gastric contents or pulmonary contusion, or the 
result of indirect insults such as non-pulmonary sepsis, polytrauma or transfusion associated 
acute lung injury. ARDS is further associated with acute inflammation,[3] and the rapid 
accumulation of neutrophils in the lung interstitium and alveolar space.[4] In addition, 
neutrophil counts remain higher in the BAL fluid of ARDS non-survivors compared to 
survivors.[5] The excessive accumulation of neutrophils in ARDS has therefore been directly 
implicated in disease pathogenesis and poor clinical outcome.[6] 
 
The migration of neutrophils into inflamed lungs is mediated by multiple factors, of which 
cell adhesion molecules and chemokines are thought to be the most important.[7] The 
chemokine CXCL8 (IL-8) is considered to be the archetypal neutrophil chemoattractant. 
Indeed, the levels of CXCL8 have been positively correlated with the number of neutrophils 
recovered from patients with ARDS,[8] and with disease severity.[9, 10] However, several 
studies have reported other chemokines may be elevated in ARDS.[11] Furthermore, we have 
recently reported that neutrophil recruitment into the lung airspaces, in response to LPS-
induced lung inflammation, is mediated by the chemokines CCL2 and CCL7,[12] while 
CCL7 regulates neutrophil recruitment in response to acute infection with the bacterium 
Streptococcus pneumoniae.[13] 
 
In this report we aim to gain a better understanding of the potential roles of CCL2 and CCL7 
in ARDS by focussing on their contribution to neutrophil recruitment. To this end we 
measured the levels of CCL2 and CCL7 in samples obtained from a human LPS-challenge 
model of acute lung injury and two separate cohorts of patients with ARDS. We investigated 
the contribution of CCL2 and CCL7 to the neutrophil chemotactic activity of human ARDS 
BAL fluid and assessed the chemotactic response of neutrophils to CCL2 and CCL7 in the 
context of the classical neutrophil chemokine CXCL8. Finally, we analysed the chemokine 
receptor expression on neutrophils derived from the blood and bronchoalveolar lavage fluid 
of patients with ARDS to determine if the receptor expression patterns change during 
neutrophil transmigration into the airspaces.  
  
MATERIALS AND METHODS 
Human LPS challenge and ARDS sample collection 
Healthy subjects (age 25.8 ± 5.5 yr; mean ± S.D.) were challenged with nebulised 0.9% 
saline or 50 μg LPS (E. coli serotype O26:B6; Sigma, UK) in sterile saline, as part of a 
previously published study.[14] Bronchoalveolar lavage (BAL) was performed 6 hours after 
challenge according to standard guidelines and prepared for analysis as previously 
described.[14] Saline challenged (n=5) and LPS challenged (n=25) BAL fluid samples were 
used to measure the protein levels of CCL2 and CCL7 by ELISA (R&D Systems) according 
to the manufacturer’s instructions. 
 
Mechanically ventilated patients within the intensive care unit of the Royal Victoria Hospital, 
Belfast, Northern Ireland were diagnosed with ARDS according to the consensus conference 
definition as previous described.[15] Baseline BAL fluid samples, before administration of 
drug or placebo, from a randomised clinical trial (The HARP Study) were used for this study 
in order to measure CCL2 (n=18) and CCL7 (n=18) protein levels.[16] Samples were 
prepared as previously described.[16] A second cohort, again from two previously described, 
randomized placebo-controlled clinical trials (the BALTI and VINDALOO trials),[17, 18] 
were used to assess CCL2 and CCL7 protein levels in the BAL fluid from post-operative 
oesophagectomy patients who were at risk of developing ARDS, but did not, compared to 
those who did develop ARDS (n=20 for each, ARDS defined as PaO2/FIO2 ratio of <300 
mm Hg). Random samples from both studies were used. Local institution and research ethics 
committee approval was obtained. Written informed consent from the legal representative of 
the patient or retrospective informed consent was obtained from the patient if possible. 
 
For flow cytometry analysis, adult patients over the age of 18 with suspected or confirmed 
community acquired pneumonia with ARDS who required mechanical ventilation were 
recruited. ARDS was defined as meeting the American-European consensus definition of 
ARDS.[15] Inclusion and exclusion criteria are defined in Supplementary Table 1 and patient 
clinical details in Supplementary Table 2. Ethics approval was obtained from the London - 
South East research ethics committee (ref: 13/LO/274). Informed consent was obtained from 
legal representatives of the subjects and retrospective informed consent from the individual 
where possible.  Bronchoscopy was performed on mechanically ventilated patients via the 
endotracheal tube. Bronchoalveolar lavage was performed in the lobe that appeared to be 
most affected on chest radiograph or computed tomography. BAL was performed as 
previously described.[14] Total cell counts were obtained using a haemocytometer. 
 
Neutrophil isolation 
Neutrophils were isolated from the blood of healthy volunteers. 20 ml blood was layered onto 
10 ml 6% dextran (from leuconostoc spp, MR 450,00; Sigma-Aldrich) in sterile 0.9% saline 
and 20 ml PBS.  The solution was left to sediment for 45 min. The buffy coat layer was 
removed and centrifuged at 300 g for 5 min in 50 ml PBS, the leukocyte-rich layer removed 
and resuspended in 55% Percol (GE Healthcare). A Percol gradient was prepared from 81% 
and 67% Percol and the resuspended leukocytes layered on top (in 55% Percol). The Percol 
gradient was centrifuged for 30 min at 700 g. The neutrophil layer was removed and washed 
in PBS followed by centrifugation at 300 g for 10 min. Neutrophils were resuspended in 1 ml 
ddH2O for 30 sec and resuspended in 20 ml PBS. Cells were centrifuged and resuspended in 
RPMI-1640 (Sigma-Aldrich). Isolated neutrophils had a purity >98% (Supplementary Figure 
1). 
 
Neutrophil chemotaxis assay 
ChemoTX plates (Neuro Probe) were used throughout (3 µm pores in a 96-well plate) 
employing 5 × 10
4
 neutrophils per well in RPMI-1640. Chemotaxis of isolated human 
neutrophils was measured in response to human BAL fluid (described above), with or without 
10 µg/ml anti-human CCL2 or CCL7 neutralising antibody (anti-human CCL2 279-MC, 
R&D Systems, anti-human CCL7 AF-282-NA, R&D Systems), 10 µg/ml anti-human CXCL8 
neutralising antibody (anti-human IL-8 AB-208-NA, R&D Systems) or 20 μg/ml polyclonal-
Ig control (R&D Systems) diluted 1:1 in RPMI-1640. The concentration of antibody used 
exceeded that required to neutralise the amount of chemokine in human ARDS BAL fluid (at 
least 10-fold excess; 10 μg/ml antibody has ND50 5-20 μg/ml chemokine). BAL fluid was 
incubated for 20 min with each neutralising antibody in the lower chamber, prior to the 
addition of 5 × 10
4
  neutrophils per well onto the upper membrane. At least 18 BAL fluid 
samples from different patients were used and each sample was run in triplicate. Neutrophils 
from the blood of multiple healthy human volunteers were used throughout. Recombinant 
human CXCL8 (IL-8), CCL2 and CCL7 (Peprotech) were used at various concentrations, 
resuspended in RPMI-1640 and placed in the lower chamber of the ChemoTX plate. 
Neutrophils were placed on the upper membrane and incubated at 37°C in 5% CO2 for 1 h. 
Migrated neutrophils were counted using a haemocytometer and the chemotactic index 
calculated (number of migrated neutrophils following treatment versus medium control). 
 
Flow cytometry analysis. 
30 ml of red cell lysis buffer (Roche, UK) was added to 3 ml of blood for 15 min. 20 ml of 
PBS was added and sample was centrifuged at 300 g for 5 min. BAL fluid cell pellets were 
resuspended in 1 ml red cell lysis buffer for 10 min. Cells were re-suspended in 1 ml PBS. 
Non-specific binding was blocked with 10% FBS in PBS.  Single stained controls and 
fluorescence minus one (FMO) controls were included. Neutrophils were gated using anti-
CD14 (Becton Dickinson (BD)), anti-CD16 (R&D Systems) and anti-HLA-DR (BD) 
antibodies (gating strategy in Supplementary Figure 2). Chemokine receptor expression was 
assessed following incubation with anti-CXCR1 (BD), anti-CXCR2, anti-CCR1, anti-CCR2 
and anti-CCR3 antibodies (all R&D Systems). Following 20 min incubation, samples were 
washed twice with 100 µl of 1% BSA in PBS and centrifuged at 300 g for 3 min at each wash 
and the supernatant discarded. Cells were re-suspended in 100 µl of 4% PFA and were kept at 
4°C in the dark until acquisition on a FACS Verse flow cytometer (BD). 
 
Statistical analysis. 
Statistical analysis was performed using one way ANOVA with Neuman Keuls post hoc test. 
P-values are presented within each figure.  
 
 
  
RESULTS 
CCL2 and CCL7 are elevated in ARDS BAL fluid. 
We have previously reported that the chemokines CCL2 and CCL7 are elevated in the lungs 
of mice challenged with either LPS or infected with S. pneumoniae, and that neutralising 
these chemokines inhibits neutrophil accumulation in BAL fluid.[12, 13] In order to translate 
these findings into the human disease setting, we first collected BAL fluid from healthy 
volunteers that were challenged with LPS (50 mg) or saline. The levels of both CCL2 (figure 
1A) and CCL7 (figure 1B) were increased in the BAL fluid isolated from LPS challenged 
individuals. Furthermore, patients with a clinical diagnosis of ARDS had elevated levels of 
CCL2 (figure 1A) and CCL7 (figure 1B) in BAL fluid compared to normal controls and 
higher levels of these chemokines compared to LPS challenged volunteers. In comparison, 
the levels of CXCL8 in ARDS BAL fluid previously reported by Craig et al. (2011) ranged 
between 40-9721 pg/ml (mean 3277, s.d. 3684).[16] In a second, independent cohort of 
patients with a clinical diagnosis of ARDS following oesophagectomy, levels of CCL2 
(figure 1C) and CCL7 (figure 1D), were increased compared to post-operative patients at 
high risk of developing ARDS but remained free of clinical diagnosis. Collectively, these 
findings suggest that CCL2 and CCL7 may play a role in the pathogenesis of ARDS in 
humans.  
 
CCL2 and CCL7 significantly contribute to the chemotactic potency of ARDS BAL 
fluid. 
Having demonstrated that CCL2 and CCL7 are elevated in BAL fluid isolated from ARDS 
patients, we next sought to elucidate whether CCL2 and CCL7 contribute to neutrophil 
recruitment in ARDS. First, we demonstrated that ARDS BAL fluid is highly chemotactic for 
human neutrophils compared to BAL fluid from healthy volunteers (figure 2A). In order to 
determine the contribution of CCL2 and CCL7 to the chemotactic activity of ARDS BALF, 
we neutralised both chemokines using specific antibodies. Compared to the maximal 
chemotactic activity of ARDS BAL fluid, neutralising the classical neutrophil chemokine, 
CXCL8, significantly decreased neutrophil chemotaxis (Figure 2B and C). Neutralising either 
CCL2 (figure 2B) or CCL7 (figure 2C) also decreased neutrophil chemotaxis towards ARDS 
BAL fluid, but a combination of either anti-CXCL8 plus anti-CCL2 (figure 2B) or a 
combination of anti-CXCL8 plus anti-CCL7 (figure 2C) caused a cumulative decrease in the 
neutrophil chemotactic response to ARDS BAL fluid. Taken together, these data suggest that 
CCL2 and CCL7 may contribute to the recruitment of neutrophils in ARDS by synergising 
with CXCL8. 
 
CCL2 and CCL7 enhance neutrophil chemotaxis to CXCL8. 
We next compared the neutrophil chemotactic activity of CCL2 and CCL7 to that of CXCL8. 
Neutrophils migrated towards CXCL8 in a concentration-dependent manner (figure 3A), with 
maximal chemoattraction at 50 ng/ml. CCL2 (figure 3B) and CCL7 (figure 3C) alone caused 
a small but non-significant amount of chemotaxis of neutrophils over a range of 
concentrations. However, when combined with a sub-optimal dose of CXCL8 (5 ng/ml), both 
CCL2 (figure 3B) and CCL7 (figure 3C) significantly increased neutrophil chemotaxis. The 
data further suggest that CCL2 and CCL7 enhance neutrophil chemotaxis by synergising with 
CXCL8. 
 
BAL fluid neutrophils from ARDS patients modify their chemokine receptor 
expression. 
We have previously demonstrated, in a mouse model of LPS-induced acute lung 
inflammation, that neutrophils can alter their expression of chemokine receptors when 
migrating into inflamed lung.[12] Therefore, in order to determine whether the cell surface 
chemokine receptor expression on neutrophils changes during neutrophil transmigration in 
ARDS, we examined whether the surface expression of CXCR1, CXCR2 (receptors for 
CXCL8), and CCR1, CCR2 and CCR3 (receptors for CCL2 and CCL7) differed on 
neutrophils isolated from the blood and BAL fluid of ARDS patients. The conventional 
neutrophil chemokine receptors CXCR1 and CXCR2 were highly expressed on neutrophils 
(CD16+, CD14-, HLA-DR-; gating strategy for BAL fluid and blood, Supplementary Figure 
2) isolated from the blood of ARDS patients (figure 4A). In contrast, neutrophils isolated 
from the ARDS patient BAL fluid exhibited a significant decrease in cell-surface CXCR1 
expression relative to the levels expressed by blood neutrophils (figure 4A). The expression 
of CXCR2 on ARDS BAL fluid neutrophils was more heterogeneous (figure 4B), with no 
significant alteration in expression levels. The expression of the CCL2 and CCL7 chemokine 
receptors CCR1, CCR2 and CCR3 on ARDS patient blood neutrophils was low compared to 
that of CXCR1 and CXCR2 (figure 4C, D and E). The expression of CCR1 and CCR3 on 
ARDS patient BALF neutrophils was not significantly different compared with ARDS patient 
blood neutrophils (figure 4C and E). However, the expression of CCR2 was significantly 
elevated on neutrophils isolated from ARDS BAL fluid (figure 4D) relative to the expression 
levels measured on blood neutrophils (the mean fluorescent intensity for each chemokine 
receptor in the blood and BAL fluid is presented in Supplementary Figure 3). Taken together, 
these data show that neutrophil chemokine receptor expression is plastic and changes during 
neutrophil transmigration from the blood to the airspaces during ARDS and further that these 
neutrophils may gain responsiveness to CCL2 and CCL7 by expressing CCR2. 
 
  
DISCUSSION 
In the present study we aimed to determine the role of CCL2 and CCL7 in influencing 
neutrophil chemotaxis in the context of ARDS. We have previously demonstrated that CCL2 
and CCL7 are elevated in a mouse model of LPS-induced acute lung inflammation,[12] and a 
mouse model of S. pneumoniae infection.[13] Furthermore, neutralisation of either CCL2 or 
CCL7 reduced the number of neutrophils isolated from the BAL fluid of LPS treated mice, 
while neutralising CCL7 reduced neutrophil numbers following pneumococcal infection. 
However, the contribution of these chemokines in the setting of human ARDS is not known. 
 
ARDS is associated with an increase in several pro-inflammatory cytokines, chemokines and 
growth-factors. Of note, IL-1β, TNF, IL-6 and CXCL8 are considered to be central mediators 
of the inflammatory immune response during ARDS pathogenesis.[19] Activation of tissue-
resident alveolar macrophages, alveolar epithelium and the endothelium, establishes a lung 
environment conducive to the recruitment of inflammatory cells into the airspace.[6] 
Neutrophils comprise the majority of cells recruited into the lung and although they are 
important for the clearance of pathogens, they are thought to contribute to the disruption of 
the epithelial-endothelial barrier in ARDS.[20] The result of a damaged alveolar-endothelial 
unit is the leakage of protein-rich fluid into the airspace, which in turn compromises gaseous 
exchange and promotes respiratory failure.  
 
The chemokine CXCL8 is considered to be the archetypal neutrophil chemoattractant, and 
levels of CXCL8 have been directly associated with the number of neutrophils recruited into 
the inflamed lung during ARDS, as well as with disease severity and poor clinical 
outcome.[21-23] Although CCL2 has previously been shown to be elevated in BAL fluid 
from patients with ARDS,[11] its specific role in mediating neutrophil migration in this 
disease setting has not been comprehensively explored. Furthermore, the closely related 
chemokine family member, CCL7, has largely been overlooked in inflammatory lung 
diseases. CCL2 and CCL7 are conventionally considered to mediate the recruitment of 
monocytes and macrophages into sites of inflammation in response to various inflammatory 
insults,[24] including LPS,[25] and the bacterium Listeria monocytogenes.[26] In humans, 
CCL2 and CCL7 have been shown to differentially induce the chemotaxis of macrophages, 
with CCL7 being the only chemokine to induce the migration of M1 and M2 
macrophages.[27] More recently, it has been demonstrated that CCL2 and CCL7 can also 
function as chemoattractants for mouse,[28, 29] and human neutrophils.[30] We now show, 
for the first time, that CCL2 and CCL7 contribute to the neutrophil chemotactic activity of 
ARDS BAL fluid and that they synergise with CXCL8 to promote neutrophil chemotaxis.  
 
Even though they are closely related chemokines, CCL2 and CCL7 differ in their biophysical 
characteristics. While CCL2 is a ligand restricted to the CCR2 receptor,[31] CCL7 is more 
promiscuous and can bind and signal via CCR1, CCR2 and CCR3,[32] and may therefore be 
able to influence the migratory capacity of multiple cell types compared to CCL2. In 
addition, CCL7 is able to bind to glycosaminoglycan (GAG) polysaccharides with higher 
affinity, so that CCL7 may form a more robust chemotactic gradient compared to CCL2.[33] 
This additional GAG-binding property of CCL7 may also account for lower amounts of 
detectable unbound CCL7 in body fluids compared to CCL2. These are important 
considerations which need to be taken into account when designing new therapeutics that 
target chemokine family members.  
 
In both chemokine neutralisation studies and in chemotaxis assays using recombinant human 
chemokines, we demonstrated that a level of synergy exists between CXCL8 and CCL2 or 
CCL7 in promoting neutrophil migration. It has previously been shown that CCL7 can 
synergise with CXCL6, in a mouse model of peritoneal inflammation,[34] and with CXCL10 
in mouse models of acid-induced lung injury and influenza infection.[29] Certain chemokines 
are also able to act cooperatively by forming heterodimers. For example, CCL5 and CXCL4 
heterodimers are elevated in ARDS and in mouse models of lung injury, while destabilising 
these complexes reduced sepsis and LPS-induced lung injury in mice.[35] Although CXCL8, 
and most other chemokines, can form homodimers and even tetramers, the different three-
dimensional configuration of CXC- compared to CC-chemokines makes heterodimer 
formation between family members more likely than mixed CXC-CC heterodimers.[36] For 
example, CXCL8 readily forms a heterodimer with CXCL4 (platelet factor 4), while CCL2 
can form heterodimers with CCL5 and CCL8. However, there is currently no direct evidence 
that CXCL8 can form heterodimers with either CCL2 or CCL7. In addition, CCL7 is 
considered to function as an obligate monomer and therefore highly unlikely to dimerise 
under these conditions.[33] Furthermore, dimerization is largely thought to increase the 
stability of chemokines in physiological fluids but is independent of receptor activation.[37] 
 
The synergistic effect between CXCL8 and CCL2 or CCL7 is therefore most likely due to 
increased receptor occupancy on neutrophils, which in turn accounts for heightened 
chemotaxis towards multiple chemokines. Previous studies using recombinant chemokines 
reported that both CCL2 and CCL7 can synergise with CXCL8 to enhance neutrophil 
migration, with CCL7 being more effective than CCL2.[38, 39] Our data confirms the 
synergistic effect between these chemokines and highlights its potential importance in the 
ARDS disease setting. Human neutrophils isolated from the BAL fluid of COPD patients 
have also been reported to express higher levels of CCR1, CCR2 and CCR3 and CCL2, 
CCL3, CCL4 and CCL11 were able to induce chemotaxis of neutrophils isolated from COPD 
patient BAL fluid.[30] This and our current study therefore suggest that neutrophils are 
capable of responding to a number of CC and CXC chemokines other than CXCL8 and its 
closely related family members. 
 
We previously demonstrated that in mouse models of ALI, neutrophils differentially express 
CXCR and CCR chemokine receptors on their cell surface depending on the tissue micro-
compartment in which they reside.[12] In order to determine if this is also the case in human 
ARDS, we analysed neutrophils from the blood and BAL fluid of ARDS patients. Compared 
to blood neutrophils, BAL fluid neutrophils expressed significantly lower levels of CXCR1 
but higher levels of CCR2, suggesting that human neutrophils can also gain responsiveness to 
different chemokine sub-sets depending on the tissue microenvironment in which they reside. 
The increased expression of CCR2 on ARDS BAL fluid neutrophils further suggests that 
neutrophils are capable of responding to CCL2 and CCL7 within airspaces in this disease 
setting, although the factors that regulate CCR2 expression on neutrophils will need to be 
fully explored in the future.  
 
Our study has some limitations in that although we demonstrated that CCL2 and CCL7 levels 
are elevated in ARDS, we would have ideally also included studies using a comparator 
control group of mechanically ventilated patients without ARDS.  To address this, we 
analysed a separate cohort of oesophagectomy patients with and without ARDS and 
demonstrated that CCL2 and CCL7 levels are significantly increased in patients who went on 
to develop ARDS. 
 
In conclusion, our data indicate that CCL2 and CCL7 levels are elevated in BAL fluid 
samples from ARDS patients and that these chemokines contribute to the chemotactic activity 
of ARDS BAL fluid by synergising with the conventional neutrophil chemoattractant, 
CXCL8. Furthermore, neutrophils differentially regulate the expression of CXCR1 and CCR2 
when migrating into the broncho-alveolar compartment, thereby enabling them to gain 
responsiveness to different chemokine subsets depending on the tissue microenvironment in 
which they reside. Our neutrophil receptor expression studies further highlight that there is 
patient heterogeneity in terms of expression patterns. A clearer understanding of patient 
heterogeneity in ARDS is critical for the successful design and implementation of both new 
therapeutics and clinical trials in this disease setting.  
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FIFURE LEGENDS 
Figure 1. Elevated BAL fluid levels of CCL2 and CCL7 in a human model of acute lung 
inflammation and in ARDS patients. Healthy volunteers were challenged with 0.6% 
nebulised saline (n=5) or with 50 μg of nebulised LPS (n=25) and broncho-alveolar lavage 
was performed 6 h later. The levels of CCL2 (A) and CCL7 (B) were measured in BAL fluid 
recovered from saline and LPS challenged volunteers by ELISA (right axis). Broncho-
alveolar lavage was also performed on patients with a clinical diagnosis of ARDS and the 
levels of CCL2 (A) and CCL7 (B) were measured (n=18) in recovered ARDS BAL fluid by 
ELISA (left axis). BAL fluid was also recovered from a second cohort of patients who 
underwent surgical oesophagectomy who were either at risk of developing ARDS (n=20) or 
who went on to develop ARDS (n=20). The levels of CCL2 (C) and CCL7 (D) were 
measured in recovered BAL fluid by ELISA. Power calculations were based on previous 
studies with alpha=0.05; power=0.8; difference between means=1.5 (50% reduction); 
standard deviation=1.6. Statistical analysis was performed using one way ANOVA with 
Neuman Keuls post hoc test.  
 
Figure 2. CXCL8, CCL2 and CCL7 contribute to the neutrophil chemotactic activity of 
ARDS BAL fluid. Human neutrophils were isolated from the blood of healthy volunteers and 
chemotaxis was measured across 3 µm membranes (ChemoTX, NeuroProbe) in response to 
media alone, healthy volunteer BAL fluid (n=11) or BAL fluid from ARDS patients (n=18) 
(A). Neutrophil chemotaxis was measured as the chemotactic index (number of migrated 
neutrophils following treatment versus medium control) after 1 h (healthy BAL fluid, left 
axis; ARDS BAL fluid, right axis). Neutrophil chemotaxis towards BAL fluid obtained from 
patients with ARDS was measured in the presence of polyclonal Ig-control (20 μg/ml), 
neutralising anti-CXCL8 (10 μg/ml), anti-CCL2 (10 μg/ml) and a combination (10 μg/ml of 
each) of the two antibodies (B) or anti-CXCL8 (10 μg/ml), anti-CCL7 (10 μg/ml) and a 
combination (10 μg/ml of each) of the two antibodies (C). Antibodies were incubated in the 
presence of ARDS BAL fluid for 20 min prior to the addition of isolated neutrophils. 
Differences in neutrophil chemotaxis between treatment groups were measured as the 
percentage of maximal chemotaxis to ARDS BAL fluid alone (n=18 ARDS BAL fluid 
samples using neutrophils isolated from multiple healthy human volunteers). Statistical 
analysis was performed using one way ANOVA with Neuman Keuls post hoc test. 
 
Figure 3. Human neutrophils migrate toward recombinant CXCL8, CCL2 and CCL7. 
Human neutrophils were isolated from the blood of healthy volunteers and chemotaxis was 
measured across 3 µm membranes (ChemoTX, NeuroProbe) in response to recombinant 
human CXCL8, CCL2 and CCL7 (A), over a range of concentrations as stated. Neutrophil 
chemotaxis was also measured in response to a sub-optimal concentration of recombinant 
human CXCL8 (5 ng/ml) in combination with recombinant human CCL2 (B) or recombinant 
human CCL7 (C) across a range of concentrations as stated (n=3 independent experiments 
using different healthy volunteer donors). Neutrophil chemotaxis was measured as the 
chemotactic index (number of migrated neutrophils following treatment versus medium 
control) after 1 h. Statistical analysis was performed using one way ANOVA with Neuman 
Keuls post hoc test. 
 
Figure 4. Neutrophils differentially regulate chemokine receptors during ARDS. 
Bronchoalveolar lavage fluid and blood was recovered from patients with a clinical diagnosis 
of ARDS (patient details in Supplementary Table 2). Flow cytometry analysis of neutrophils 
was performed by gating on CD16+, CD14-, HLA-DR- leukocyte populations. The 
neutrophil population was further verified by FSC and SSC properties (details in 
Supplementary Figure 2). The expression of CXCR1 (A), CXCR2 (B), CCR1 (C), CCR2 (D) 
and CCR3 (E) on neutrophils from the blood of ARDS patients was compared to neutrophils 
from the BAL fluid of matching ARDS patients (n=10). Data is represented as the as the ratio 
of mean fluorescent intensity (MFI) of each chemokine receptor expressed on BAL fluid 
neutrophils versus blood neutrophils (direct measurements of MFI are presented in 
Supplementary Figure 3). Statistical analysis was performed using one way ANOVA with 
Neuman Keuls post hoc test. 
 
